Free Trial

Corbus Pharmaceuticals (CRBP) News Today

Corbus Pharmaceuticals logo
$7.36 -0.04 (-0.54%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$7.39 +0.03 (+0.41%)
As of 07:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRBP Latest News

Corbus Pharmaceuticals Holdings, Inc. stock logo
Tang Capital Management LLC Has $2.86 Million Stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)
Tang Capital Management LLC trimmed its stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 59.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 242,653 shares of the biopharmaceutical compa
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Rating of "Buy" by Analysts
Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have received an average rating of "Buy" from the ten ratings firms that are presently covering the firm, Marketbeat Ratings reports. Nine analysts have rated the stock with a buy recommendation and one has given a str
Corbus Pharmaceuticals Holdings, Inc. stock logo
Prosight Management LP Purchases 140,000 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)
Prosight Management LP increased its position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 107.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 270,000 shares of the biopharmace
Corbus Pharmaceuticals Holdings, Inc. stock logo
Orbimed Advisors LLC Raises Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)
Orbimed Advisors LLC grew its stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 28.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,172,287 shares of the biopharmaceutical company's stock after buying an additional 259,735 shares
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Sold by Barclays PLC
Barclays PLC lessened its stake in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 85.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 18,156 shares of the biopharmaceutical company's stock after selling
Corbus Pharmaceuticals Holdings, Inc. stock logo
Q2 EPS Forecast for Corbus Pharmaceuticals Cut by Analyst
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Stock analysts at B. Riley decreased their Q2 2025 earnings estimates for Corbus Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 6th. B. Riley analyst K. Patel now forecasts that the biopharma
Corbus Pharmaceuticals Holdings, Inc. stock logo
HC Wainwright Has Pessimistic Outlook of CRBP Q2 Earnings
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities research analysts at HC Wainwright reduced their Q2 2025 earnings per share estimates for shares of Corbus Pharmaceuticals in a research report issued on Wednesday, May 7th. HC Wainwright analyst A. Maldonado now anticip
Corbus Pharmaceuticals Holdings, Inc. stock logo
Q2 EPS Estimates for Corbus Pharmaceuticals Cut by Wedbush
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities researchers at Wedbush decreased their Q2 2025 earnings estimates for shares of Corbus Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 6th. Wedbush analyst R. Driscoll now anticipates
Corbus Pharmaceuticals Holdings, Inc. stock logo
Q2 Earnings Estimate for CRBP Issued By William Blair
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities research analysts at William Blair issued their Q2 2025 earnings estimates for Corbus Pharmaceuticals in a report issued on Tuesday, May 6th. William Blair analyst A. Hsieh anticipates that the biopharmaceutical company
Corbus Pharmaceuticals Holdings, Inc. stock logo
Price T Rowe Associates Inc. MD Sells 160,933 Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)
Price T Rowe Associates Inc. MD cut its holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 49.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 164,735 shares of the biophar
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals (NASDAQ:CRBP) Given New $56.00 Price Target at Oppenheimer
Oppenheimer cut their target price on shares of Corbus Pharmaceuticals from $60.00 to $56.00 and set an "outperform" rating for the company in a research note on Wednesday.
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target Cut to $40.00 by Analysts at HC Wainwright
HC Wainwright dropped their price target on shares of Corbus Pharmaceuticals from $50.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday.
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals (NASDAQ:CRBP) Posts Earnings Results, Misses Expectations By $0.13 EPS
Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($1.26) by ($0.13).
Corbus Pharmaceuticals Holdings, Inc. stock logo
Boothbay Fund Management LLC Decreases Position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)
Boothbay Fund Management LLC reduced its stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 75.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,534 shares of the biopharmaceutical comp
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday
Corbus Pharmaceuticals (NASDAQ:CRBP) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-corbus-pharmaceuticals-holdings-inc-stock/)
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Bought by Renaissance Technologies LLC
Renaissance Technologies LLC grew its stake in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 769.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 139,10
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Consensus Rating of "Buy" by Brokerages
Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have received a consensus rating of "Buy" from the ten analysts that are presently covering the stock, MarketBeat Ratings reports. Nine research analysts have rated the stock with a buy rating and one has given a stron
Corbus Pharmaceuticals Holdings, Inc. stock logo
Altium Capital Management LLC Raises Holdings in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)
Altium Capital Management LLC boosted its stake in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) by 97.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 385,000 shares of the biopharmaceutical comp
Corbus Pharmaceuticals management to meet with Piper Sandler
Corbus announces first patient dosed in Phase 1 CRB-913 study
Corbus Pharmaceuticals Holdings, Inc. stock logo
B. Riley Lifts Earnings Estimates for Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities researchers at B. Riley raised their FY2025 earnings estimates for shares of Corbus Pharmaceuticals in a research report issued to clients and investors on Thursday, March 13th. B. Riley analyst K. Patel now anticipates
Corbus Pharmaceuticals Holdings, Inc. stock logo
HC Wainwright Issues Positive Estimate for CRBP Earnings
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a research note issued to investors on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now forecasts that the
Corbus Pharmaceuticals Holdings, Inc. stock logo
What is B. Riley's Forecast for CRBP Q1 Earnings?
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Analysts at B. Riley issued their Q1 2025 EPS estimates for Corbus Pharmaceuticals in a research report issued to clients and investors on Thursday, March 13th. B. Riley analyst K. Patel anticipates that the biopharmaceutical com
Corbus Pharmaceuticals Holdings, Inc. stock logo
What is Lifesci Capital's Estimate for CRBP Q1 Earnings?
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Stock analysts at Lifesci Capital boosted their Q1 2025 EPS estimates for Corbus Pharmaceuticals in a research report issued on Tuesday, March 11th. Lifesci Capital analyst M. Belghiti now forecasts that the biopharmaceutical com
Corbus Pharmaceuticals Holdings, Inc. stock logo
Wedbush Reaffirms Outperform Rating for Corbus Pharmaceuticals (NASDAQ:CRBP)
Wedbush reissued an "outperform" rating and issued a $51.00 price target on shares of Corbus Pharmaceuticals in a research note on Wednesday.
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals (NASDAQ:CRBP) Receives "Buy" Rating from HC Wainwright
HC Wainwright reissued a "buy" rating and issued a $50.00 price target (down previously from $75.00) on shares of Corbus Pharmaceuticals in a report on Wednesday.
Corbus Pharmaceuticals (CRBP) Gets a Buy from RBC Capital
Corbus Pharmaceuticals Holdings, Inc. stock logo
Jefferies Financial Group Lowers Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $53.00
Jefferies Financial Group dropped their target price on shares of Corbus Pharmaceuticals from $70.00 to $53.00 and set a "buy" rating on the stock in a research report on Tuesday.
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals (NASDAQ:CRBP) Posts Quarterly Earnings Results, Beats Expectations By $0.24 EPS
Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.78) EPS for the quarter, topping analysts' consensus estimates of ($1.02) by $0.24.
Corbus Pharmaceuticals (CRBP) Gets a Buy from William Blair
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded to Sell at StockNews.com
StockNews.com upgraded shares of Corbus Pharmaceuticals to a "sell" rating in a research report on Thursday.
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals (NASDAQ:CRBP) Earns Outperform Rating from Analysts at William Blair
William Blair began coverage on shares of Corbus Pharmaceuticals in a research note on Friday. They set an "outperform" rating for the company.
Corbus Pharmaceuticals initiated with an Outperform at William Blair
Corbus Pharmaceuticals Holdings, Inc. stock logo
Corbus Pharmaceuticals (NASDAQ:CRBP) Given Buy Rating at HC Wainwright
HC Wainwright restated a "buy" rating and set a $75.00 price target on shares of Corbus Pharmaceuticals in a report on Tuesday.
Corbus Pharmaceuticals announces data from its US, UK study of CRB-701
RBC Capital Sticks to Its Buy Rating for Corbus Pharmaceuticals (CRBP)
Get Corbus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.

CRBP Media Mentions By Week

CRBP Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRBP
News Sentiment

0.93

1.03

Average
Medical
News Sentiment

CRBP News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRBP Articles
This Week

4

3

CRBP Articles
Average Week

Get Corbus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:CRBP) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners